Complete Response to Intravesical Gemcitabine in Non-Muscle Invasive
Bladder Cancer Patient after BCG Failure A Case Report and Literature
Review
- Fouad Nahhat
, - Modar Doyya,
- Hazem Ksiri
Abstract
Bladder cancer treatment remains a challenge to every oncologist. We
report the case of a 57-year-old man with BCG-refractory bladder cancer,
who had a complete response to the intravesical Gemcitabine to shine the
light on the role of Gemcitabine as a bladder sparing treatment in
BCG-failure patients.29 Jun 2022Submitted to Clinical Case Reports 12 Jul 2022Submission Checks Completed
12 Jul 2022Assigned to Editor
31 Jul 2022Reviewer(s) Assigned
01 Aug 2022Review(s) Completed, Editorial Evaluation Pending
21 Aug 2022Editorial Decision: Revise Minor
01 Sep 20221st Revision Received
02 Sep 2022Submission Checks Completed
02 Sep 2022Assigned to Editor
02 Sep 2022Review(s) Completed, Editorial Evaluation Pending
08 Sep 2022Editorial Decision: Accept
